MBX Biosciences, Inc.
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.97% | 25.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.55% | -5.11% | |||
| Operating Income | -42.55% | 5.11% | |||
| Income Before Tax | -53.21% | 14.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -53.21% | 14.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.21% | 14.09% | |||
| EBIT | -42.55% | 5.11% | |||
| EBITDA | -42.58% | 5.04% | |||
| EPS Basic | -53.14% | 83.24% | |||
| Normalized Basic EPS | -28.92% | 80.09% | |||
| EPS Diluted | -53.14% | 83.24% | |||
| Normalized Diluted EPS | -28.92% | 80.09% | |||
| Average Basic Shares Outstanding | 0.06% | 412.50% | |||
| Average Diluted Shares Outstanding | 0.06% | 412.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||